Telomere Length and Recurrence Risk after Curative Resection in Patients with Early-Stage Non–Small-Cell Lung Cancer: A Prospective Cohort Study

Background: We hypothesized that telomere length in peripheral blood would have significant predictive value for risk of recurrence after curative resection in non–small-cell lung cancer (NSCLC). Methods: This prospective study included 473 patients with histologically confirmed early stage NSCLC who underwent curative therapy at MD Anderson Cancer Center between 1995 and 2008. Relative telomere length (RTL) of peripheral leukocytes was measured by real-time polymerase chain reaction. The risk of recurrence was estimated as hazard ratios (HRs) and 95% confidence intervals (CIs) using a multivariable Cox proportional hazard regression model. Results: Median duration of follow-up was 61 months, and 151 patients (32%) had developed recurrence at time of analysis. Patients who developed recurrence had significantly longer mean RTL compared with those without recurrence (1.13 versus 1.07, p = 0.046). A subgroup analysis indicates that women had longer RTL compared with men (1.12 versus 1.06, p = 0.025), and the patients with adenocarcinoma demonstrated longer RTL compared with those with other histologic types (1.11 versus 1.05, p = 0.042). To determine whether longer RTL in women and adenocarcinoma subgroup would predict risk of recurrence, multivariate Cox analysis adjusting for age, sex, stage, pack year and treatment regimens was performed. Longer telomeres were significantly associated with higher risk of developing recurrence in women (hazard ratio [HR], 2.25; 95% confidence interval [CI], 1.02–4.96, p = 0.044) and adenocarcinoma subgroups (HR, 2.19; 95% CI, 1.05–4.55, p = 0.036). The increased risk of recurrence due to long RTL was more apparent in women with adenocarcinoma (HR, 2.67; 95% CI, 1.19–6.03, p = 0.018). Conclusions: This is the first prospective study to suggest that long RTL is associated with recurrence in early stage NSCLC after curative resection. Women and adenocarcinoma seem to be special subgroups in which telomere biology may play an important role.

[1]  E. Riboli,et al.  Leukocyte Telomere Length in Relation to Pancreatic Cancer Risk: A Prospective Study , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[2]  N. Rothman,et al.  Telomere length in white blood cell DNA and lung cancer: a pooled analysis of three prospective cohorts. , 2014, Cancer research.

[3]  Joe Y. Chang,et al.  Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians. , 2014, Cancer research.

[4]  Thomas M. Keane,et al.  POT1 loss-of-function variants predispose to familial melanoma , 2014, Nature Genetics.

[5]  Geoff Der,et al.  Gender and telomere length: Systematic review and meta-analysis , 2014, Experimental Gerontology.

[6]  E. Susser,et al.  Correction: Corrigendum: Telomeres shorten at equivalent rates in somatic tissues of adults , 2013, Nature Communications.

[7]  Shigeo Sato,et al.  Telomere Length Influences Cancer Cell Differentiation In Vivo , 2013, Molecular and Cellular Biology.

[8]  N. Rothman,et al.  Longer Telomere Length in Peripheral White Blood Cells Is Associated with Risk of Lung Cancer and the rs2736100 (CLPTM1L-TERT) Polymorphism in a Prospective Cohort Study among Women in China , 2013, PloS one.

[9]  E. Susser,et al.  Telomeres shorten at equivalent rates in somatic tissues of adults , 2013, Nature Communications.

[10]  N. Saijo.  Advances in Personalized Therapy for Lung Cancer , 2011 .

[11]  M. Kogo,et al.  Increased telomerase activity and hTERT expression in human salivary gland carcinomas. , 2011, Oncology letters.

[12]  I. Shih,et al.  Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma , 2011, Modern Pathology.

[13]  S. Ballereau,et al.  TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres , 2011, Gut.

[14]  Q. Wei,et al.  Shortened Telomere Length Is Associated with Increased Risk of Cancer: A Meta-Analysis , 2011, PloS one.

[15]  R. Beijersbergen,et al.  EGFR overexpression induces activation of telomerase via PI3K/AKT‐mediated phosphorylation and transcriptional regulation through Hif1‐alpha in a cellular model of oral–esophageal carcinogenesis , 2011, Cancer science.

[16]  H. Nan,et al.  Genetic variants in telomere-maintaining genes and skin cancer risk , 2011, Human Genetics.

[17]  R. Hayes,et al.  The association of telomere length and genetic variation in telomere biology genes a , 2010, Human mutation.

[18]  F. Kronenberg,et al.  Telomere length and risk of incident cancer and cancer mortality. , 2010, JAMA.

[19]  B. Ponder,et al.  Telomere length in prospective and retrospective cancer case-control studies. , 2010, Cancer research.

[20]  Wei Zheng,et al.  A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33 , 2010, Nature Genetics.

[21]  T. Spector,et al.  A genome-wide association study identifies a novel locus on chromosome 18q12.2 influencing white cell telomere length , 2009, Journal of Medical Genetics.

[22]  G. Roos,et al.  Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. , 2009, Cancer research.

[23]  G. Roos,et al.  The Individual Blood Cell Telomere Attrition Rate Is Telomere Length Dependent , 2009, PLoS genetics.

[24]  Wei Chen,et al.  Leukocyte Telomere Dynamics: Longitudinal Findings Among Young Adults in the Bogalusa Heart Study , 2008, American journal of epidemiology.

[25]  Simon Heath,et al.  Lung cancer susceptibility locus at 5p15.33 , 2008, Nature Genetics.

[26]  Richard J Stephens,et al.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Park,et al.  Telomere length and the risk of lung cancer , 2008, Cancer science.

[28]  Manuel Benito,et al.  Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. , 2008, Lung cancer.

[29]  Göran Roos,et al.  Breast cancer survival is associated with telomere length in peripheral blood cells. , 2008, Cancer research.

[30]  M. Jarstfer,et al.  The human telomere and its relationship to human disease, therapy, and tissue engineering. , 2007, Frontiers in bioscience : a journal and virtual library.

[31]  Edward L Spitznagel,et al.  Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Ewa Wójcik,et al.  Pretreatment Serum Levels of Cytokines and Cytokine Receptors in Patients with Non-Small Cell Lung Cancer, and Correlations with Clinicopathological Features and Prognosis , 2006, Oncology.

[33]  T. Mattfeldt,et al.  Sex-specific telomere length profiles and age-dependent erosion dynamics of individual chromosome arms in humans , 2006, Cytogenetic and Genome Research.

[34]  J. Shim,et al.  Effect of Long-Term Hormone Therapy on Telomere Length in Postmenopausal Women , 2005, Yonsei medical journal.

[35]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[36]  A. Marchetti,et al.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Lingner,et al.  Human Protection of Telomeres 1 (POT1) Is a Negative Regulator of Telomerase Activity In Vitro , 2005, Molecular and Cellular Biology.

[38]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Jun Qin,et al.  The Human Rap1 Protein Complex and Modulation of Telomere Length* , 2004, Journal of Biological Chemistry.

[40]  Jun Qin,et al.  PTOP interacts with POT1 and regulates its localization to telomeres , 2004, Nature Cell Biology.

[41]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[42]  S. Kyo,et al.  Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines , 2004, Oncogene.

[43]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[44]  J. Shay,et al.  Hallmarks of senescence in carcinogenesis and cancer therapy , 2004, Oncogene.

[45]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[46]  Tzu-chin Wu,et al.  Loss of telomerase activity may be a potential favorable prognostic marker in lung carcinomas. , 2003, Lung Cancer.

[47]  T. Lange,et al.  POT1 as a terminal transducer of TRF1 telomere length control , 2003, Nature.

[48]  R. DePinho,et al.  Connecting chromosomes, crisis, and cancer. , 2002, Science.

[49]  K. Anderson,et al.  Cytokines modulate telomerase activity in a human multiple myeloma cell line. , 2002, Cancer research.

[50]  S. Murakami,et al.  Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway , 2002, Oncogene.

[51]  R. Cawthon.  Telomere measurement by quantitative PCR. , 2002, Nucleic acids research.

[52]  J. Skurnick,et al.  Telomere Length as an Indicator of Biological Aging: The Gender Effect and Relation With Pulse Pressure and Pulse Wave Velocity , 2001, Hypertension.

[53]  T. Lange,et al.  Identification of Human Rap1 Implications for Telomere Evolution , 2000, Cell.

[54]  S. Kyo,et al.  Estrogen activates telomerase. , 1999, Cancer research.

[55]  R. Insel,et al.  Up‐regulation of telomerase in human B lymphocytes occurs independently of cellular proliferation and with expression of the telomerase catalytic subunit , 1999, European journal of immunology.

[56]  D. Broccoli,et al.  Human telomeres contain two distinct Myb–related proteins, TRF1 and TRF2 , 1997, Nature Genetics.

[57]  I. Wistuba,et al.  Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. , 1997, Cancer research.

[58]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[59]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[60]  Bas van Steensel,et al.  Control of telomere length by the human telomeric protein TRF1 , 1997, Nature.

[61]  H. Igarashi,et al.  Telomerase activity is induced in human peripheral B lymphocytes by the stimulation to antigen receptor. , 1997, Blood.

[62]  K. Eguchi,et al.  Serum levels of cytokines in patients with untreated primary lung cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.